mRNA drug offers hope for treating a devastating childhood disease

Elie Dolgin

DOI: https://doi.org/10.1038/d41586-024-00954-4

IF: 64.8

2024-04-04

Nature

Abstract:Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs. Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.

multidisciplinary sciences

What problem does this paper attempt to address?

Unlocking the promise of mRNA therapeutics

Eduarde Rohner,Ran Yang,Kylie S. Foo,Alexander Goedel,Kenneth R. Chien

DOI: https://doi.org/10.1038/s41587-022-01491-z

IF: 46.9

2022-11-04

Nature Biotechnology

Abstract:The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19) has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical trials of mRNA therapeutics include studies of paracrine vascular endothelial growth factor (VEGF) mRNA for heart failure and of CRISPR–Cas9 mRNA for a congenital liver-specific storage disease. However, a series of challenges remains to be addressed before mRNA can be established as a general therapeutic modality with broad relevance to both rare and common diseases. An array of new technologies is being developed to surmount these challenges, including approaches to optimize mRNA cargos, lipid carriers with inherent tissue tropism and in vivo percutaneous delivery systems. The judicious integration of these advances may unlock the promise of biologically targeted mRNA therapeutics, beyond vaccines and other immunostimulatory agents, for the treatment of diverse clinical indications.

biotechnology & applied microbiology
mRNA-based therapeutics: looking beyond COVID-19 vaccines

Hamideh Parhiz,Elena N Atochina-Vasserman,Drew Weissman

DOI: https://doi.org/10.1016/S0140-6736(23)02444-3

2024-03-23

Abstract:Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA-encoded proteins, without the need to enter the nucleus or the risk of genomic integration, makes them desirable tools for treatment of a range of diseases, from infectious diseases to cancer and monogenic disorders. The rapid pace and ease of mass-scale manufacturability of mRNA-based therapeutics supported the global response to the COVID-19 pandemic. Nonetheless, challenges remain with regards to mRNA stability, duration of expression, delivery efficiency, and targetability, to broaden the applicability of mRNA therapeutics beyond COVID-19 vaccines. By learning from the rapidly expanding preclinical and clinical studies, we can optimise the mRNA platform to meet the clinical needs of each disease. Here, we will summarise the recent advances in mRNA technology; its use in vaccines, immunotherapeutics, protein replacement therapy, and genomic editing; and its delivery to desired specific cell types and organs for development of a new generation of targeted mRNA-based therapeutics.
mRNA: A promising platform for cancer immunotherapy

Byoungjae Kong,Yelee Kim,Eun Hye Kim,Jung Soo Suk,Yoosoo Yang

DOI: https://doi.org/10.1016/j.addr.2023.114993

Abstract:Messenger RNA (mRNA) is now in the limelight as a powerful tool for treating various human diseases, especially malignant tumors, thanks to the remarkable clinical outcomes of mRNA vaccines using lipid nanoparticle technology during the COVID-19 pandemic. Recent promising preclinical and clinical results that epitomize the advancement in mRNA and nanoformulation-based delivery technologies have highlighted the tremendous potential of mRNA in cancer immunotherapy. mRNAs can be harnessed for cancer immunotherapy in forms of various therapeutic modalities, including cancer vaccines, adoptive T-cell therapies, therapeutic antibodies, and immunomodulatory proteins. This review provides a comprehensive overview of the current state and prospects of mRNA-based therapeutics, including numerous delivery and therapeutic strategies.
mRNA therapies: Pioneering a new era in rare genetic disease treatment

Guobo Shen,Jian Liu,Hanmei Yang,Na Xie,Yang Yang

DOI: https://doi.org/10.1016/j.jconrel.2024.03.056

IF: 11.467

2024-04-14

Journal of Controlled Release

Abstract:Rare genetic diseases, often referred to as orphan diseases due to their low prevalence and limited treatment options, have long posed significant challenges to our medical system. In recent years, Messenger RNA (mRNA) therapy has emerged as a highly promising treatment approach for various diseases caused by genetic mutations. Chemically modified mRNA is introduced into cells using carriers like lipid-based nanoparticles (LNPs), producing functional proteins that compensate for genetic deficiencies. Given the advantages of precise dosing, biocompatibility, transient expression, and minimal risk of genomic integration, mRNA therapies can safely and effectively correct genetic defects in rare diseases and improve symptoms. Currently, dozens of mRNA drugs targeting rare diseases are undergoing clinical trials. This comprehensive review summarizes the progress of mRNA therapy in treating rare genetic diseases. It introduces the development, molecular design, and delivery systems of mRNA therapy, highlighting their research progress in rare genetic diseases based on protein replacement and gene editing. The review also summarizes research progress in various rare disease models and clinical trials. Additionally, it discusses the challenges and future prospects of mRNA therapy. Researchers are encouraged to join this field and collaborate to advance the clinical translation of mRNA therapy, bringing hope to patients with rare genetic diseases.

pharmacology & pharmacy,chemistry, multidisciplinary
mRNA vaccines in disease prevention and treatment

Gang Zhang,Tianyu Tang,Yinfeng Chen,Xing Huang,Tingbo Liang

DOI: https://doi.org/10.1038/s41392-023-01579-1

IF: 39.3

2023-09-21

Signal Transduction and Targeted Therapy

Abstract:mRNA vaccines have emerged as highly effective strategies in the prophylaxis and treatment of diseases, thanks largely although not totally to their extraordinary performance in recent years against the worldwide plague COVID-19. The huge superiority of mRNA vaccines regarding their efficacy, safety, and large-scale manufacture encourages pharmaceutical industries and biotechnology companies to expand their application to a diverse array of diseases, despite the nonnegligible problems in design, fabrication, and mode of administration. This review delves into the technical underpinnings of mRNA vaccines, covering mRNA design, synthesis, delivery, and adjuvant technologies. Moreover, this review presents a systematic retrospective analysis in a logical and well-organized manner, shedding light on representative mRNA vaccines employed in various diseases. The scope extends across infectious diseases, cancers, immunological diseases, tissue damages, and rare diseases, showcasing the versatility and potential of mRNA vaccines in diverse therapeutic areas. Furthermore, this review engages in a prospective discussion regarding the current challenge and potential direction for the advancement and utilization of mRNA vaccines. Overall, this comprehensive review serves as a valuable resource for researchers, clinicians, and industry professionals, providing a comprehensive understanding of the technical aspects, historical context, and future prospects of mRNA vaccines in the fight against various diseases.

biochemistry & molecular biology,cell biology
mRNA biotherapeutics landscape for rare genetic disorders

V Rajesh Iyer,P Praveen,Bhagyashree D Kaduskar,Shivranjani C Moharir,Rakesh K Mishra

DOI: https://doi.org/10.1007/s12038-023-00415-6

2024-02-20

Journal of Biosciences

Abstract:The medical emergency of COVID-19 brought to the forefront mRNA vaccine technology where the mRNA vaccine candidates mRNA-1273 and BNT162b2 displayed superlative and more than 90% efficacy in protecting against SARS-CoV2 infections. Rare genetic disorders are rare individually, but collectively they are common and represent a medical emergency. In mRNA biotherapeutic technology, administration of a therapeutic protein-encoding mRNA-nanoparticle formulation allows for in vivo production of therapeutic proteins to functionally complement the protein functions lacking in rare disease patients. The platform nature of mRNA biotherapeutic technology propels rare disease drug discovery and, owing to the scalable and synthetic nature of mRNA manufacturing, empowers parallel product development using a universal production pipeline. This review focuses on the advantages of mRNA biotherapeutic technology over current therapies for rare diseases and provides summaries for the proof-of-concept preclinical studies performed to demonstrate the potential of mRNA biotherapeutic technology. Apart from preclinical studies, this review also spotlights the clinical trials currently being conducted for mRNA biotherapeutic candidates. Currently, seven mRNA biotherapeutic candidates have entered clinical trials for rare diseases, and of them, 3 candidates entered in the year 2023 alone. The rapid pace of clinical development promises a future where, as with mRNA vaccines for COVID-19, mRNA biotherapeutic technology would combat an emergency of rare genetic disorders.

biology
mRNA vaccine: a potential therapeutic strategy

Yang Wang,Ziqi Zhang,Jingwen Luo,Xuejiao Han,Yuquan Wei,Xiawei Wei

DOI: https://doi.org/10.1186/s12943-021-01311-z

IF: 37.3

2021-02-16

Molecular Cancer

Abstract:Abstract mRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, we have witnessed the development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based mRNA vaccines. The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases. Finally, we will discuss the challenge of mRNA vaccines against bacterial and parasitic diseases.

oncology,biochemistry & molecular biology
Cancer mRNA vaccines: clinical advances and future opportunities

Elias J. Sayour,David Boczkowski,Duane A. Mitchell,Smita K. Nair

DOI: https://doi.org/10.1038/s41571-024-00902-1

IF: 78.8

2024-05-19

Nature Reviews Clinical Oncology

Abstract:mRNA vaccines have been revolutionary in terms of their rapid development and prevention of SARS-CoV-2 infections during the COVID-19 pandemic, and this technology has considerable potential for application to the treatment of cancer. Compared with traditional cancer vaccines based on proteins or peptides, mRNA vaccines reconcile the needs for both personalization and commercialization in a manner that is unique to each patient but not beholden to their HLA haplotype. A further advantage of mRNA vaccines is the availability of engineering strategies to improve their stability while retaining immunogenicity, enabling the induction of complementary innate and adaptive immune responses. Thus far, no mRNA-based cancer vaccines have received regulatory approval, although several phase I–II trials have yielded promising results, including in historically poorly immunogenic tumours. Furthermore, many early phase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations and iterations that might optimize the activity of these agents.

oncology
How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development

Qiongyu Duan,Tianyu Hu,Qiuxia Zhu,Xueying Jin,Feng Chi,Xiaodong Chen

DOI: https://doi.org/10.3389/fimmu.2022.974433

2022-09-12

Abstract:mRNA products are therapies that are regulated from the post-transcriptional, pre-translational stage of a gene and act upstream of protein synthesis. Compared with traditional small molecule drugs and antibody drugs, mRNA drugs had the advantages of simple design, short development cycle, strong target specificity, wide therapeutic field, and long-lasting effect. mRNA drugs were now widely used in the treatment of genetic diseases, tumors, and viral infections, and are expected to become the third major class of drugs after small molecule drugs and antibody drugs. The delivery system technology was the key to ensuring the efficacy and safety of mRNA drugs, which plays an important role in protecting RNA structure, enhancing targeting ability, reducing the dose of drug delivery, and reducing toxic side effects. Lipid nanoparticles (LNP) were the most common delivery system for mRNA drugs. In recent years, mRNA drugs have seen rapid development, with the number of drugs on the market increasing each year. The success of commercializing mRNA vaccines has driven a wave of nucleic acid drug development. mRNA drugs were clinically used in genetic diseases, oncology, and infectious diseases worldwide, while domestic mRNA clinical development was focused on COVID-19 vaccines, with more scope for future indication expansion.
mRNA-Based Cancer Vaccines: Advancements and Prospects

Lijin Wu,Weicheng Yi,Shiyu Yao,Sitao Xie,Ruizi Peng,Jing Zhang,Weihong Tan

DOI: https://doi.org/10.1021/acs.nanolett.4c03296

IF: 10.8

2024-10-08

Nano Letters

Abstract:The success of mRNA COVID-19 vaccines has reinvigorated research and interest in mRNA-based cancer vaccines. Despite promising results in clinical trials, therapeutic mRNA-based cancer vaccines have not yet been approved for human use. These vaccines are designed to trigger tumor regression, establish enduring antitumor memory, and mitigate adverse reactions. However, challenges such as tumor-induced immunosuppression and immunoresistance significantly hinder their application. Here, we provide...

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
mRNA vaccines for infectious diseases — advances, challenges and opportunities

Norbert Pardi,Florian Krammer

DOI: https://doi.org/10.1038/s41573-024-01042-y

IF: 112.288

2024-10-05

Nature Reviews Drug Discovery

Abstract:The concept of mRNA-based vaccines emerged more than three decades ago. Groundbreaking discoveries and technological advancements over the past 20 years have resolved the major roadblocks that initially delayed application of this new vaccine modality. The rapid development of nucleoside-modified COVID-19 mRNA vaccines demonstrated that this immunization platform is easy to develop, has an acceptable safety profile and can be produced at a large scale. The flexibility and ease of antigen design have enabled mRNA vaccines to enter development for a wide range of viruses as well as for various bacteria and parasites. However, gaps in our knowledge limit the development of next-generation mRNA vaccines with increased potency and safety. A deeper understanding of the mechanisms of action of mRNA vaccines, application of novel technologies enabling rational antigen design, and innovative vaccine delivery strategies and vaccination regimens will likely yield potent novel vaccines against a wide range of pathogens.

pharmacology & pharmacy,biotechnology & applied microbiology
mRNA Vaccine-A New Cancer Treatment Strategy.

Chuan Xu,Binghuo Wu,Qi Yang,Meng-Wan Wu,Hong Wu,Shu-Ting Deng,Chen-hui Cao,Tian Tan

DOI: https://doi.org/10.2174/1568009623666230222124424

2023-02-22

Current Cancer Drug Targets

Abstract:The corresponding mRNA vaccines Comirnaty (BNT162b2) and Spikevax (mRNA-1273) have been authorized for emergency use since the COVID-19 outbreak. Most clinical researches have also discovered that the mRNA vaccine is a revolutionary strategy for preventing and treating numerous diseases, including cancers. Unlike viral vectors or DNA vaccines, mRNA vaccines cause the body to directly produce proteins following injection. Delivery vectors and mRNAs that encode tumor antigens or immunomodulatory molecules work together to trigger an anti-tumor response. Before mRNA vaccines may be employed in clinical trials, a number of challenges need to be resolved. These include establishing effective and safe delivery systems, generating successful mRNA vaccines against diverse types of cancers, and proposing improved combination therapy. Therefore, we need to improve vaccine-specific recognition and develop mRNA delivery mechanisms. This review summarizes the complete mRNA vaccines' elemental composition and discusses recent research progress and future direction for mRNA tumor vaccines.

Medicine
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery

Geonhee Han,Dahye Noh,Hokyung Lee,Sangmin Lee,Sehoon Kim,Hong Yeol Yoon,Soo Hyeon Lee

DOI: https://doi.org/10.1016/j.addr.2023.114973

Abstract:RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality.
mRNA vaccines in the prevention and treatment of diseases

Yangzhuo Gu,Jiangyao Duan,Na Yang,Yuxin Yang,Xing Zhao

DOI: https://doi.org/10.1002/mco2.167

2022-08-25

Abstract:Messenger ribonucleic acid (mRNA) vaccines made their successful public debut in the effort against the COVID-19 outbreak starting in late 2019, although the history of mRNA vaccines can be traced back decades. This review provides an overview to discuss the historical course and present situation of mRNA vaccine development in addition to some basic concepts that underly mRNA vaccines. We discuss the general preparation and manufacturing of mRNA vaccines and also discuss the scientific advances in the in vivo delivery system and evaluate popular approaches (i.e., lipid nanoparticle and protamine) in detail. Next, we highlight the clinical value of mRNA vaccines as potent candidates for therapeutic treatment and discuss clinical progress in the treatment of cancer and coronavirus disease 2019. Data suggest that mRNA vaccines, with several prominent advantages, have achieved encouraging results and increasing attention due to tremendous potential in disease management. Finally, we suggest some potential directions worthy of further investigation and optimization. In addition to basic research, studies that help to facilitate storage and transportation will be indispensable for practical applications.
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems

Zhongyan Wu,Weilu Sun,Hailong Qi

DOI: https://doi.org/10.3390/vaccines12080873

2024-08-01

Abstract:mRNA vaccines are leading a medical revolution. mRNA technologies utilize the host's own cells as bio-factories to produce proteins that serve as antigens. This revolutionary approach circumvents the complicated processes involved in traditional vaccine production and empowers vaccines with the ability to respond to emerging or mutated infectious diseases rapidly. Additionally, the robust cellular immune response elicited by mRNA vaccines has shown significant promise in cancer treatment. However, the inherent instability of mRNA and the complexity of tumor immunity have limited its broader application. Although the emergence of pseudouridine and ionizable cationic lipid nanoparticles (LNPs) made the clinical application of mRNA possible, there remains substantial potential for further improvement of the immunogenicity of delivered antigens and preventive or therapeutic effects of mRNA technology. Here, we review the latest advancements in mRNA vaccines, including but not limited to target selection and delivery systems. This review offers a multifaceted perspective on this rapidly evolving field.
mRNA therapeutics for central nervous system disorders

Yuta Fukushima,Keiji Itaka

DOI: https://doi.org/10.2745/dds.37.247

2022-07-25

Drug Delivery System

Abstract:The high efficacy of mRNA COVID-19 vaccine encourages the wider application of mRNA therapeutics. Protein replacement therapy with mRNA therapeutics is a promising alternative approach for administering trophic factor proteins in central nervous system disorders or enzyme replacement therapy in inherited enzyme deficient diseases. Although the concept to deliver the mRNA in vivo as a drug was demonstrated as early as 1990, mRNA instability hindered subsequent research development. The polymer-based carrier, polyplex nanomicelle, is a novel carrier for in vivo mRNA administration. Here, we introduce the researches of in vivo mRNA administration using the nanomicelle carrier to treat animal models, especially focusing on the central nervous system disorders including Alzheimer’s disease, spinal cord injury and ischemic brain disease. We discuss the advantages of mRNA therapeutics and the characteristics of diseases which are highly suitable for mRNA therapeutics.
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

Jiao Wei,Ai-Min Hui

DOI: https://doi.org/10.1016/j.ctrv.2022.102405

Abstract:mRNA vaccines have gained popularity over the last decade as a versatile tool for developing novel therapeutics. The recent success of coronavirus disease (COVID-19) mRNA vaccine has unlocked the potential of mRNA technology as a powerful therapeutic platform. In this review, we apprise the literature on the various types of cancer vaccines, the novel platforms available for delivery of the vaccines, the recent progress in the RNA-based therapies and the evolving role of mRNA vaccines for various cancer indications, along with a future strategy to treat the patients. Literature reveals that despite multifaceted challenges in the development of mRNA vaccines, the promising and durable efficacy of the RNA in pre-clinical and clinical studies deserves consideration. The introduction of mRNA-transfected DC vaccine is an approach that has gained interest for cancer vaccine development due to its ability to circumvent the necessity of DC isolation, ex vivo cultivation and re-infusion. The selection of appropriate antigen of interest remains one of the major challenges for cancer vaccine development. The rapid development and large-scale production of mRNA platform has enabled for the development of both personalized vaccines (mRNA 4157, mRNA 4650 and RO7198457) and tetravalent vaccines (BNT111 and mRNA-5671). In addition, mRNA vaccines combined with checkpoint modulators and other novel medications that reverse immunosuppression show promise, however further research is needed to discover which combinations are most successful and the best dosing schedule for each component. Each delivery route (intradermal, subcutaneous, intra tumoral, intranodal, intranasal, intravenous) has its own set of challenges to overcome, and these challenges will decide the best delivery method. In other words, while developing a vaccine design, the underlying motivation should be a reasonable combination of delivery route and format. Exploring various administration routes and delivery route systems has boosted the development of mRNA vaccines.
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

Yingying Shi,Meixing Shi,Yi Wang,Jian You

DOI: https://doi.org/10.1038/s41392-024-02002-z

IF: 39.3

2024-11-21

Signal Transduction and Targeted Therapy

Abstract:In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge in interest can be largely attributed to the demonstration of distinct advantages offered by various mRNA molecules, alongside the rapid advancements in nucleic acid delivery systems. It is noteworthy that the immunogenicity of mRNA drugs presents a double-edged sword. In the context of immunotherapy, extra supplementation of adjuvant is generally required for induction of robust immune responses. Conversely, in non-immunotherapeutic scenarios, immune activation is unwanted considering the host tolerability and high expression demand for mRNA-encoded functional proteins. Herein, mainly focused on the linear non-replicating mRNA, we overview the preclinical and clinical progress and prospects of mRNA medicines encompassing vaccines and other therapeutics. We also highlight the importance of focusing on the host-specific variations, including age, gender, pathological condition, and concurrent medication of individual patient, for maximized efficacy and safety upon mRNA administration. Furthermore, we deliberate on the potential challenges that mRNA drugs may encounter in the realm of disease treatment, the current endeavors of improvement, as well as the application prospects for future advancements. Overall, this review aims to present a comprehensive understanding of mRNA-based therapies while illuminating the prospective development and clinical application of mRNA drugs.

biochemistry & molecular biology,cell biology
mRNA therapy shows promise for metabolic disorder

Sarah Crunkhorn

DOI: https://doi.org/10.1038/d41573-024-00071-x

IF: 112.288

2024-04-24

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 23 April 2024; doi:10.1038/d41573-024-00071-x mRNA therapy shows promise for metabolic disorder

pharmacology & pharmacy,biotechnology & applied microbiology
The landscape of mRNA nanomedicine

Xiangang Huang,Na Kong,Xingcai Zhang,Yihai Cao,Robert Langer,Wei Tao

DOI: https://doi.org/10.1038/s41591-022-02061-1

IF: 82.9

2022-11-11

Nature Medicine

Abstract:Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer–BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.

biochemistry & molecular biology,cell biology,medicine, research & experimental

mRNA drug offers hope for treating a devastating childhood disease

Unlocking the promise of mRNA therapeutics

mRNA-based therapeutics: looking beyond COVID-19 vaccines

mRNA: A promising platform for cancer immunotherapy

mRNA therapies: Pioneering a new era in rare genetic disease treatment

mRNA vaccines in disease prevention and treatment

mRNA biotherapeutics landscape for rare genetic disorders

mRNA vaccine: a potential therapeutic strategy

Cancer mRNA vaccines: clinical advances and future opportunities

How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development

mRNA-Based Cancer Vaccines: Advancements and Prospects

mRNA vaccines for infectious diseases — advances, challenges and opportunities

mRNA Vaccine-A New Cancer Treatment Strategy.

Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery

mRNA vaccines in the prevention and treatment of diseases

Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems

mRNA therapeutics for central nervous system disorders

The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

mRNA therapy shows promise for metabolic disorder

The landscape of mRNA nanomedicine